A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-29

Study Completion Date

2022-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim is to check the effect of a single dose of soticlestat in adults with moderate or mild liver failure compared to healthy adults with normal liver function.

Participants will check into the study clinic for 8 days. During the stay, one oral dose of soticlestat will be given and the participant will be monitored. The clinic staff will follow up with the participant about a week after discharge from the clinic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

NCT05857644

Liver Diseases Hepatic Impairment

COMPLETED PHASE1

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425

NASH

COMPLETED PHASE1

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347

Liver Diseases

COMPLETED PHASE1

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032

Healthy Hepatic Insufficiency

COMPLETED PHASE1

F573 for Injection for the Treatment of Liver Injury/Failure

NCT05689645

Acute Liver Failure Acute-On-Chronic Liver Failure

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called soticlestat (TAK-935). The study will assess the safety and tolerability of single oral dose of soticlestat in participants with moderate or mild Hepatic Impairment (HI) compared to healthy participants matched by age (mean ±10 years), sex (±2 per sex), and body mass index (BMI, mean ±10 percent \[%\]) with normal hepatic function.

The study will enroll approximately 40 participants. Participants will be assigned to following study arms:

* Arm 1, Moderate HI: Soticlestat 300 milligram (mg) (Child-Pugh Class B)
* Arm 2, Mild HI: Soticlestat 300 mg (Child-Pugh Class A)
* Arm 3, Normal hepatic function: Soticlestat 300 mg

All participants will receive single oral dose of study drug. The data will be collected and stored in electronic case report form (eCRF).

This multi-center trial will be conducted in the United States and Hungary. The overall duration of the study is approximately 42 days. Participants will be followed up for 14 days after the last dose of study drug for a follow-up assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Impairment Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1, Moderate HI: Soticlestat 300 mg

Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with moderate HI.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat tablets.

Arm 2, Mild HI: Soticlestat 300 mg

Soticlestat 300 mg, tablets, orally, once on Day 1 to participant with mild HI.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat tablets.

Arm 3, Normal hepatic function: Soticlestat 300 mg

Soticlestat 300 mg, tablets, orally, once on Day 1 to healthy participants.

Group Type EXPERIMENTAL

Soticlestat

Intervention Type DRUG

Soticlestat tablets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soticlestat

Soticlestat tablets.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TAK-935

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has a BMI greater than or equal to (\>=) 18.0 and less than or equal to (\<=) 40.0 kilogram per square meter (kg/m\^2), at screening. At least 50% of the participants will be required to be of BMI \>=18.0 and \<=35.0 kg/m\^2, at screening.

* Supine blood pressure (BP) is \>=80/40 millimeter of mercury (mmHg) (asymptomatic) and \<=150/95 mmHg at screening;
* Supine pulse rate (PR) is \>=40 beats per minute (bpm) and \<=99 bpm, at screening;
* QT interval corrected for heart rate using Fridericia's formula (QTcF) is \<=500 millisecond (msec) and ECG findings considered normal or not clinically significant by the Investigator or designee, at screening.
2. Must have had chronic HI for at least 3 months before screening, and the HI must be stable, that is, no significant changes in hepatic function in the 30 days preceding screening (or since the last visit if within 6 months before screening) and treatment with stable doses of medication. Has a score on the Child-Pugh Class at screening as follows:

* (Arm 1) Moderate HI, Child-Pugh Class B: \>=7 and \<=9
* (Arm 2) Mild HI, Child-Pugh Class A: \>=5 and \<=6
3. Should not have renal dysfunction as demonstrated by a relatively adequate renal function (creatinine clearance \>=50 milliliter per minute \[mL/min\]), at screening.

B. For Healthy Participants

1. Has a BMI \>=18.0 and \<=40.0 kg/m\^2, at screening. At least 50% of the participants will be required to be of BMI \>=18.0 and \<=35.0 kg/m\^2, at screening. Healthy participants will be matched to hepatic impaired participants in this study by age (mean ±10 years), sex (±2 per sex), and BMI, mean ±10%.

* Supine BP is \>=90/40 mmHg and \<=150/95 mmHg, at screening;
* Supine PR is \>=40 bpm and \<=99 bpm, at screening;
* QTcF is \<=450 msec (males) or \<=470 msec (females) and ECG findings considered normal or not clinically significant by the Investigator or designee, at screening;
* Liver function tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin \<= the upper limit of normal (ULN) at screening and check-in.
2. Should not have renal dysfunction as demonstrated by a relatively adequate renal function (creatinine clearance \>=60 mL/min), at screening.

C. For Participants with Hepatic Impairment and Healthy Participants

1\. Continuous non-smoker or moderate smoker (\<=10 cigarettes/day or the equivalent) before screening. Participant must agree to consume no more than 5 cigarettes or equivalent/day from the 7 days prior check-in and until discharge from the Clinical Research Unit (CRU).

Exclusion Criteria

1. Has history or presence of clinically significant medical or psychiatric condition or disease (aside from HI) or presence of psychotic disorders such as psychosis, delusions, or schizophrenia in the opinion of the Investigator or designee.
2. Has a history of liver or other solid organ transplant.
3. Positive result at screening for human immunodeficiency virus (HIV). Hepatitis B surface antigen (HBsAg) positive participants are allowed to be enrolled if Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is below 1000 copies per milliliter (/mL) in the plasma. Participants with moderate or mild HI who are positive for Hepatitis C virus antibodies (HCVAb) can be enrolled but must not have detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) in the plasma.

B. For Healthy Participants

1. Has history or presence of clinically significant medical or psychiatric condition or disease or presence of psychotic disorders such as psychosis, delusions, or schizophrenia in the opinion of the Investigator or designee.
2. Positive results at screening for HIV, HBsAg, or HCV.

C. For Participants with Hepatic Impairment and Healthy Participants

1. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to dosing.
2. Any positive responses on the Columbia-Suicide Severity Rating Scale (C-SSRS) or has a risk of suicide according to the Investigator's judgment based on the assessment of the C-SSRS at screening or check-in or has made a suicide attempt in the previous 12 months prior to dosing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes